The company claims a 69% response rate with iSCIB1+, but only in a “target population”.

The group touts a 72% ORR with SCIB1, but full Scope data have been pushed back into 2025.

Data in the coming months will inform which immunotherapy the UK company takes into pivotal development.

Projects from the likes of BioNTech, Transgene and Scancell will feature, but still have much to prove.